The Sick Times: “Three clinical trials for Long COVID are testing JAK inhibitors to treat immune dysregulation”
‘abrocitinib (Cibinqo), baricitinib (Olumiant) & upadacitinib (Rinvoq). All are JAK inhibitors, which target specific inflammation pathways’
thesicktimes.org/2025/08/05/t...
‘abrocitinib (Cibinqo), baricitinib (Olumiant) & upadacitinib (Rinvoq). All are JAK inhibitors, which target specific inflammation pathways’
thesicktimes.org/2025/08/05/t...
Three clinical trials for Long COVID are testing JAK inhibitors to treat immune dysregulation - The Sick Times
Three separate trials are testing the immunomodulator drugs abrocitinib (Cibinqo), baricitinib (Olumiant), and upadacitinib (Rinvoq). All are JAK inhibitors, which target specific inflammation pathway...
thesicktimes.org
August 5, 2025 at 6:11 PM
The Sick Times: “Three clinical trials for Long COVID are testing JAK inhibitors to treat immune dysregulation”
‘abrocitinib (Cibinqo), baricitinib (Olumiant) & upadacitinib (Rinvoq). All are JAK inhibitors, which target specific inflammation pathways’
thesicktimes.org/2025/08/05/t...
‘abrocitinib (Cibinqo), baricitinib (Olumiant) & upadacitinib (Rinvoq). All are JAK inhibitors, which target specific inflammation pathways’
thesicktimes.org/2025/08/05/t...
AbbVie Secures Rare Disease Drug Designation for Upadacitinib in Hidradenitis Suppurativa#Japan#AbbVie#Minato-ku#Hidradenitis_Suppurativa#Upadacitinib
AbbVie Secures Rare Disease Drug Designation for Upadacitinib in Hidradenitis Suppurativa
AbbVie has obtained rare disease drug designation for Upadacitinib, targeting Hidradenitis Suppurativa in Japan, addressing a significant unmet medical need.
third-news.com
September 29, 2026 at 4:19 AM
AbbVie Secures Rare Disease Drug Designation for Upadacitinib in Hidradenitis Suppurativa#Japan#AbbVie#Minato-ku#Hidradenitis_Suppurativa#Upadacitinib
Blimey. Doctors have approved me for upadacitinib. Applying for local authority funding now. It can't come soon enough.
March 20, 2025 at 4:21 PM
Blimey. Doctors have approved me for upadacitinib. Applying for local authority funding now. It can't come soon enough.
Hurrah! New rheumatoid arthritis drug has arrived: upadacitinib. Really hope it works. Same class as baricitinib, which I had before, but caused BK virus to run riot and destroy my kidneys. This time, there's no kidney left to lose...
May 7, 2025 at 10:19 AM
Hurrah! New rheumatoid arthritis drug has arrived: upadacitinib. Really hope it works. Same class as baricitinib, which I had before, but caused BK virus to run riot and destroy my kidneys. This time, there's no kidney left to lose...
the body is incredible! phase 3 trials for upadacitinib showed 75% facial repigmentation for vitiligo, an autoimmune condition where the body loses pigment. this could be the first systemic medicine, bringing so much hope to many!
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Ado
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion for upadacitinib (RINVOQ®) as a systemic treatment for non-segmental vitiligo in adul
news.abbvie.com
June 29, 2026 at 8:05 AM
the body is incredible! phase 3 trials for upadacitinib showed 75% facial repigmentation for vitiligo, an autoimmune condition where the body loses pigment. this could be the first systemic medicine, bringing so much hope to many!
Have you taken a JAK STAT inhibitor for Long COVID or ME? I'm working on a story about these drugs (baricitinib, abrocitinib, upadacitinib, and others) which are currently being investigated in clinical trials for the disease.
Reach me at: miles@thesicktimes.org or dm for signal!
Reach me at: miles@thesicktimes.org or dm for signal!
April 25, 2025 at 12:11 AM
Have you taken a JAK STAT inhibitor for Long COVID or ME? I'm working on a story about these drugs (baricitinib, abrocitinib, upadacitinib, and others) which are currently being investigated in clinical trials for the disease.
Reach me at: miles@thesicktimes.org or dm for signal!
Reach me at: miles@thesicktimes.org or dm for signal!
A Phase 3 Trial of #Upadacitinib for Giant-Cell Arteritis | NEJM
www.nejm.org/doi/full/10....
“In patients with giant-cell #arteritis, upadacitinib at a dose of 15 mg — but not 7.5 mg — with a 26-week glucocorticoid taper showed efficacy superior to that of placebo.”
#Rheumsky #GCA
www.nejm.org/doi/full/10....
“In patients with giant-cell #arteritis, upadacitinib at a dose of 15 mg — but not 7.5 mg — with a 26-week glucocorticoid taper showed efficacy superior to that of placebo.”
#Rheumsky #GCA
A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis | NEJM
Giant-cell arteritis is a systemic vasculitis with limited treatment options. The efficacy and safety of upadacitinib — a selective Janus kinase (JAK) inhibitor that blocks the signaling of several...
www.nejm.org
April 2, 2025 at 11:42 PM
A Phase 3 Trial of #Upadacitinib for Giant-Cell Arteritis | NEJM
www.nejm.org/doi/full/10....
“In patients with giant-cell #arteritis, upadacitinib at a dose of 15 mg — but not 7.5 mg — with a 26-week glucocorticoid taper showed efficacy superior to that of placebo.”
#Rheumsky #GCA
www.nejm.org/doi/full/10....
“In patients with giant-cell #arteritis, upadacitinib at a dose of 15 mg — but not 7.5 mg — with a 26-week glucocorticoid taper showed efficacy superior to that of placebo.”
#Rheumsky #GCA
A novel oral treatment option for patients with giant-cell arteritis #GCA on the horizon as per a new article in @nejm.org . Upadacitinib demonstrated superiority over the steroids taper in phase 3 trial #medsky. www.nejm.org/doi/pdf/10.1...
A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis | NEJM
Giant-cell arteritis is a systemic vasculitis with limited treatment options. The
efficacy and safety of upadacitinib — a selective Janus kinase (JAK) inhibitor that
blocks the signaling of several...
www.nejm.org
April 8, 2025 at 2:36 AM
A novel oral treatment option for patients with giant-cell arteritis #GCA on the horizon as per a new article in @nejm.org . Upadacitinib demonstrated superiority over the steroids taper in phase 3 trial #medsky. www.nejm.org/doi/pdf/10.1...
The first account was of #filgotinib, and this is of #upadacitinib. Both are Janus tyrosine kinase type 1 (JAK1) inhibitors.
November 21, 2024 at 7:29 PM
The first account was of #filgotinib, and this is of #upadacitinib. Both are Janus tyrosine kinase type 1 (JAK1) inhibitors.
Extra-musculoskeletal manifestations are an important treatment consideration for patients with spondyloarthritis. In this analysis, development of uveitis, IBD, and psoriasis was generally low with upadacitinib 15 mg, incl. numerically lower rates of uveitis vs placebo
A&R
doi.org/10.1002/art....
A&R
doi.org/10.1002/art....
December 4, 2024 at 9:04 PM
Extra-musculoskeletal manifestations are an important treatment consideration for patients with spondyloarthritis. In this analysis, development of uveitis, IBD, and psoriasis was generally low with upadacitinib 15 mg, incl. numerically lower rates of uveitis vs placebo
A&R
doi.org/10.1002/art....
A&R
doi.org/10.1002/art....
Different properties of JAK inhibitors
--> different safety and efficacy profiles
- tofacitinib: JAK 1/3 inhibition
- upadacitinib & filgotinib: JAK 1 inhibition
#IBDSky
academic.oup.com/rheumatology...
--> different safety and efficacy profiles
- tofacitinib: JAK 1/3 inhibition
- upadacitinib & filgotinib: JAK 1 inhibition
#IBDSky
academic.oup.com/rheumatology...
November 24, 2024 at 2:12 PM
Different properties of JAK inhibitors
--> different safety and efficacy profiles
- tofacitinib: JAK 1/3 inhibition
- upadacitinib & filgotinib: JAK 1 inhibition
#IBDSky
academic.oup.com/rheumatology...
--> different safety and efficacy profiles
- tofacitinib: JAK 1/3 inhibition
- upadacitinib & filgotinib: JAK 1 inhibition
#IBDSky
academic.oup.com/rheumatology...
🌟 CRP is down from 47 on Tuesday to 3.1 today. Which isn't just "not getting worse" but: a normal value?! Gonna go back in to see what it's doing Monday next week. Now to wait and see if it's just the corticosteroids (not a long term fix) or the Upadacitinib is working (please be this). #NayeHealth
July 21, 2025 at 7:37 AM
🌟 CRP is down from 47 on Tuesday to 3.1 today. Which isn't just "not getting worse" but: a normal value?! Gonna go back in to see what it's doing Monday next week. Now to wait and see if it's just the corticosteroids (not a long term fix) or the Upadacitinib is working (please be this). #NayeHealth
NEW: Three #LongCOVID clinical trials are testing JAK inhibitors, a new & powerful class of drugs approved for some autoimmune diseases. Researchers believe if they can calm down immune dysregulation, they may be able to calm down the disease process itself.
thesicktimes.org/2025/08/05/t...
thesicktimes.org/2025/08/05/t...
Three clinical trials for Long COVID are testing JAK inhibitors to treat immune dysregulation - The Sick Times
Three separate trials are testing the immunomodulator drugs abrocitinib (Cibinqo), baricitinib (Olumiant), and upadacitinib (Rinvoq). All are JAK inhibitors, which target specific inflammation pathway...
thesicktimes.org
August 5, 2025 at 7:27 PM
NEW: Three #LongCOVID clinical trials are testing JAK inhibitors, a new & powerful class of drugs approved for some autoimmune diseases. Researchers believe if they can calm down immune dysregulation, they may be able to calm down the disease process itself.
thesicktimes.org/2025/08/05/t...
thesicktimes.org/2025/08/05/t...
Patients with giant-cell arteritis need better treatments. This video, in partnership with @glaucomflecken.bsky.social, summarizes new research findings on the JAK-1 inhibitor upadacitinib in patients with giant-cell arteritis. Access the article for free: nej.md/DrG22
July 29, 2025 at 7:03 PM
Patients with giant-cell arteritis need better treatments. This video, in partnership with @glaucomflecken.bsky.social, summarizes new research findings on the JAK-1 inhibitor upadacitinib in patients with giant-cell arteritis. Access the article for free: nej.md/DrG22
In the next year or so, I'm hoping that we'll have the results for
- Nanoneedle validation study
- Several pilot / case studies for mAbs in Long Covid
- Early signals from one or more of the JAK-STAT trials (Abrocitinib, Upadacitinib)
- Nanoneedle validation study
- Several pilot / case studies for mAbs in Long Covid
- Early signals from one or more of the JAK-STAT trials (Abrocitinib, Upadacitinib)
April 19, 2025 at 1:25 AM
In the next year or so, I'm hoping that we'll have the results for
- Nanoneedle validation study
- Several pilot / case studies for mAbs in Long Covid
- Early signals from one or more of the JAK-STAT trials (Abrocitinib, Upadacitinib)
- Nanoneedle validation study
- Several pilot / case studies for mAbs in Long Covid
- Early signals from one or more of the JAK-STAT trials (Abrocitinib, Upadacitinib)
A global trial led by Western University is testing upadacitinib & pirfenidone for #LongCovid. 🧪
🎯 Target: inflammation pathways found via AI & blood protein analysis.
👩🔬Personalised to target most severe symptoms in the individual.
🖇️ tinyurl.com/2tbhfz94
#MedTwitter
🎯 Target: inflammation pathways found via AI & blood protein analysis.
👩🔬Personalised to target most severe symptoms in the individual.
🖇️ tinyurl.com/2tbhfz94
#MedTwitter
April 25, 2025 at 12:56 PM
A global trial led by Western University is testing upadacitinib & pirfenidone for #LongCovid. 🧪
🎯 Target: inflammation pathways found via AI & blood protein analysis.
👩🔬Personalised to target most severe symptoms in the individual.
🖇️ tinyurl.com/2tbhfz94
#MedTwitter
🎯 Target: inflammation pathways found via AI & blood protein analysis.
👩🔬Personalised to target most severe symptoms in the individual.
🖇️ tinyurl.com/2tbhfz94
#MedTwitter
There is an unmet need for effective, glucocorticoid-sparing treatments for patients with giant-cell arteritis. Research findings from the SELECT-GCA phase 3 trial on the JAK-1 inhibitor upadacitinib in these patients are summarized in a new Quick Take video. nej.md/4dqsugD
#MedSky
#MedSky
June 1, 2025 at 7:02 PM
There is an unmet need for effective, glucocorticoid-sparing treatments for patients with giant-cell arteritis. Research findings from the SELECT-GCA phase 3 trial on the JAK-1 inhibitor upadacitinib in these patients are summarized in a new Quick Take video. nej.md/4dqsugD
#MedSky
#MedSky
“In December 2023, Jen began a two-month trial of the immunomodulating drug upadacitinib.. Jen.. had severe #MECFS for nearly two decades.. five weeks after stopping the treatment, she went into full remission." thesicktimes.org/2025/08/05/t...
Three clinical trials for Long COVID are testing JAK inhibitors to treat immune dysregulation - The Sick Times
Three separate trials are testing the immunomodulator drugs abrocitinib (Cibinqo), baricitinib (Olumiant), and upadacitinib (Rinvoq). All are JAK inhibitors, which target specific inflammation pathway...
thesicktimes.org
September 17, 2025 at 8:26 PM
“In December 2023, Jen began a two-month trial of the immunomodulating drug upadacitinib.. Jen.. had severe #MECFS for nearly two decades.. five weeks after stopping the treatment, she went into full remission." thesicktimes.org/2025/08/05/t...
According to a retrospective cohort study by Elizabeth Spencer at Mount Sinai, #upadacitinib can be considered an effective maintenance treatment for pediatric patients with refractory #CrohnDisease.
#PediatricCrohnsDisease #PediatricIBD #IBDSky #GISky
www.docwirenews.com/post/real-wo...
#PediatricCrohnsDisease #PediatricIBD #IBDSky #GISky
www.docwirenews.com/post/real-wo...
Upadacitinib Maintenance for Pediatric CD | Gastro Today
Real-world data showed that upadacitinib is effective maintenance therapy for pediatric Crohn’s disease.
www.docwirenews.com
October 1, 2026 at 1:28 AM
According to a retrospective cohort study by Elizabeth Spencer at Mount Sinai, #upadacitinib can be considered an effective maintenance treatment for pediatric patients with refractory #CrohnDisease.
#PediatricCrohnsDisease #PediatricIBD #IBDSky #GISky
www.docwirenews.com/post/real-wo...
#PediatricCrohnsDisease #PediatricIBD #IBDSky #GISky
www.docwirenews.com/post/real-wo...
A new #LongCOVID / #PostCOVID phase III RCT by the UWO in Canada.
In this study, repurposed drugs will be tested.
In a first phase, 348 patients will take either upadacitinib (a JAK inhibitor) or pirfenidone (a medication for IPF) (or a placebo).
clinicaltrials.gov/study/NCT069...
In this study, repurposed drugs will be tested.
In a first phase, 348 patients will take either upadacitinib (a JAK inhibitor) or pirfenidone (a medication for IPF) (or a placebo).
clinicaltrials.gov/study/NCT069...
April 15, 2025 at 4:52 PM
A new #LongCOVID / #PostCOVID phase III RCT by the UWO in Canada.
In this study, repurposed drugs will be tested.
In a first phase, 348 patients will take either upadacitinib (a JAK inhibitor) or pirfenidone (a medication for IPF) (or a placebo).
clinicaltrials.gov/study/NCT069...
In this study, repurposed drugs will be tested.
In a first phase, 348 patients will take either upadacitinib (a JAK inhibitor) or pirfenidone (a medication for IPF) (or a placebo).
clinicaltrials.gov/study/NCT069...
Possible treatments for long COVID at the centre of new Western study
“The trial will test two drugs, upadacitinib and pirfenidone – which are approved for treating arthritis and lung disease”
“The trial will test two drugs, upadacitinib and pirfenidone – which are approved for treating arthritis and lung disease”
Possible treatments for long COVID at the centre of new Western study
More than 300 patients are at the centre of a Western long COVID study, which hopes to find an effective treatment for those who struggle with long COVID.
www.ctvnews.ca
April 30, 2025 at 1:02 PM
Possible treatments for long COVID at the centre of new Western study
“The trial will test two drugs, upadacitinib and pirfenidone – which are approved for treating arthritis and lung disease”
“The trial will test two drugs, upadacitinib and pirfenidone – which are approved for treating arthritis and lung disease”
Today @thesicktimes.org: an incredible deep-dive on JAK inhibitors by @mileswgriffis.bsky.social. Three research teams independently arrived at this group of drugs for Long COVID clinical trials! thesicktimes.org/2025/08/05/t...
Three clinical trials for Long COVID are testing JAK inhibitors to treat immune dysregulation - The Sick Times
Three separate trials are testing the immunomodulator drugs abrocitinib (Cibinqo), baricitinib (Olumiant), and upadacitinib (Rinvoq). All are JAK inhibitors, which target specific inflammation pathway...
thesicktimes.org
August 5, 2025 at 9:00 PM
Today @thesicktimes.org: an incredible deep-dive on JAK inhibitors by @mileswgriffis.bsky.social. Three research teams independently arrived at this group of drugs for Long COVID clinical trials! thesicktimes.org/2025/08/05/t...
Great story on JAK inhibitors being trialled for #longcovid @thesicktimes.org thesicktimes.org/2025/08/05/t...
Three clinical trials for Long COVID are testing JAK inhibitors to treat immune dysregulation - The Sick Times
Three separate trials are testing the immunomodulator drugs abrocitinib (Cibinqo), baricitinib (Olumiant), and upadacitinib (Rinvoq). All are JAK inhibitors, which target specific inflammation pathway...
thesicktimes.org
August 6, 2025 at 3:14 AM
Great story on JAK inhibitors being trialled for #longcovid @thesicktimes.org thesicktimes.org/2025/08/05/t...
Great @thesicktimes.org article on 3 upcoming #LongCovid trials on JAK inhibitors. PLRC did patient engagement and helped shape 1 of the 3 here, REVERSE-LC (baricitinib) led by @weselymd.bsky.social — who also used our scorecards for patient engagement! thesicktimes.org/2025/08/05/t...
Three clinical trials for Long COVID are testing JAK inhibitors to treat immune dysregulation - The Sick Times
Three separate trials are testing the immunomodulator drugs abrocitinib (Cibinqo), baricitinib (Olumiant), and upadacitinib (Rinvoq). All are JAK inhibitors, which target specific inflammation pathway...
thesicktimes.org
September 17, 2025 at 8:25 PM
Great @thesicktimes.org article on 3 upcoming #LongCovid trials on JAK inhibitors. PLRC did patient engagement and helped shape 1 of the 3 here, REVERSE-LC (baricitinib) led by @weselymd.bsky.social — who also used our scorecards for patient engagement! thesicktimes.org/2025/08/05/t...
Isn't it a rare disease?
Can covid-19 reactivate those slumbering infections?
www.sciencedirect.com/science/arti...
Can covid-19 reactivate those slumbering infections?
www.sciencedirect.com/science/arti...
Disseminated bartonellosis and EBV reactivation in an adolescent treated with upadacitinib
Bartonella henselae is responsible for disseminated infections in immunocompromised patients. Upadacitinib is a JAK inhibitor used since 2021 for the …
www.sciencedirect.com
May 17, 2025 at 6:18 AM
Isn't it a rare disease?
Can covid-19 reactivate those slumbering infections?
www.sciencedirect.com/science/arti...
Can covid-19 reactivate those slumbering infections?
www.sciencedirect.com/science/arti...